Skip to content

The effect of repeated remote ischaemic postconditioning on infarct size in stroke patients.

A randomized clinical trial to assess the effect of repeated remote ischaemic postconditioning on infarct size in patients with an ischaemic stroke’

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21188
Enrollment
200
Registered
2017-12-08
Start date
2018-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, CVA, herseninfarct

Interventions

Repeated remote ischaemic postconditioning (RIPostC): 4 cycles of ischaemia of the arm by inflating a blood pressure cuff around the upper arm at 20 mmHg above systolic blood pressure during 5 minutes

Sponsors

Radboudumc, Nijmegen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Informed consent - Age >18 years - Clinically diagnosed ischaemic stroke using the WHO definition for stroke (“Stroke was defined as a rapidly evolving focal neurological deficit, without positive phenomena such as twitches, jerks or myoclonus, with no other than a vascular cause”).

Exclusion criteria

Exclusion criteria: Unstable vital signs Admitted >24 hours after onset of symptoms Upper extremity injury or edema contra-indicating remote ischaemic conditioning Mastectomy on both sides MRI contra-indications

Design outcomes

Primary

MeasureTime frame
To examine the impact of repeated daily remote ischaemic postconditioning, starting on the day of an ischaemic stroke on infarct size after 4 days or at the end of hospitalization (using MRI).

Secondary

MeasureTime frame
Explore the effect of repeated daily remote ischaemic postconditioning on clinical outcome after 12 weeks (using the modified ranking score; degree of disability/dependence). Assess the impact of repeated daily remote ischaemic postconditioning on validated and frequently used markers of vascular, immune, and anti-inflammatory pathways, and relate these effects to total infarct size and clinical outcome.

Contacts

Public ContactT.R.J. Landman
Thijs.RJ.Landman@radboudumc.nl024-3614087

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)